hematology - myeloid gene panels

Lab Test name Contact Comments
UZ Leuven MolPLUZ hematology - myeloid gene panels Jolien De Bie
Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 1x/week
Test type: targeted capture NGS workflow with custom IDT xGen® Lockdown® Probes on an Illumina sequencing instrument
Genes: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DIS3, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, GFI1, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KMT2A, KRAS, MPL, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RUNX1, SAMD9, SAMD9L, SETBP1, SF3B1, SMC1A, SMC3, SRP72, SRSF2, STAG1, STAG2, TET2, TP53, U2AF1, WAS, WT1, ZRSR2
BELAC accreditation number 215-MED
Accredited:
UZA Mol. Diagn. hematology - myeloid gene panels K. Vermeulen,
M. Le Mercier,
M-B Maes
29 genes Haloplex HS NGS panel on MiSeq to screen clinically relevant genes in myeloid malignancies (incl. AML, MDS, CMML, MPN, MDS/MPN).
Genes: ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETNK1, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KMT2A, KRAS, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2.
Sample Type: Blood, Bone marrow, FFPE samples
Version date: 25/01/2021
Accredited:
UZ Gent hematology - myeloid gene panels Karl Vandepoele,
Joni Van Der Meulen,
Barbara Denys
In-house developed, capture-based (HyperCap) 68 gene panel to screen clinically relevant genes in myeloid disorders by NGS:
ANKRD26, ASXL1, ATM, BCL2, BCOR, BCORL1, BRAF, BTK, CALR, CBL, CBLB, CEBPA, CSF3R, CUX1, CXCR4, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KMT2A, KRAS, MPL, MYD88, NF1, NPM1, NOTCH1, NRAS, NUDT15, PHF6, PLCG2, PPM1D, PTPN11, RAD21, RHOA, RRAS, RUNX1, SBDS, SETBP1, SF1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, TPMT, U2AF1, UGT1A1, WT1, ZRSR2
1x/week
BELAC accreditation number 087-MED
The same gene panel is also used for certain lymfoid malignancies.
Version date: 16/03/2021
Accredited:
UZ Gent hematology - myeloid gene panels Karl Vandepoele,
Joni Van Der Meulen,
Barbara Denys
In-house developed NGS panel to screen the driver genes in presumed polycythemia vera (PV), essential thrombocytosis (ET) or primary myelofibrosis (PMF):
CALR, JAK2, MPL
1x/week
BELAC accreditation number 087-MED

For a more extensive analysis of ET or PMF: see the NGS 68 gene panel
Version date: 16/03/2021
Accredited:
CHU Liège - Hemato hematology - myeloid gene panels Dr Frédéric LAMBERT
NGS targeted sequencing after hybridization capture, Home brew assay or Sophia Myeloid Solution (MYS)
Targets: SH2B3 (LNK); CBL; ASXL1; CALR; CSF1R; CSF3R; DNMT3A; EPOR; ETNK1; EZH2; JAK1; JAK2; JAK3; KIT; MPL; NF1; PHD2; SETBP1; SRSF2; STAT5B; TET2; U2AF35; VHL; ZRSR2; BCROR; BCORL1
Full genes list available upon request.

Indications:

- MDS diagnosis if >= 1 lineage with > 10% of dysplasia BUT not all WHO criteria met; persistent, unexplained (pan)-cytopenia (>3-6 months)
- AML diagnosis & prognostication;
- Triple-negative MPNs;
- CMML & others "Overlap syndromes" diagnosis;
- Atypical/Phi-negative MPNs;

BELAC accreditation number: 128-MED
Accredited:
CHU Liège - Hemato hematology - myeloid gene panels Dr Frédéric LAMBERT & Rafael Carazo
33 Nomenclature

Familial MDS/AML syndromes; Inheritred bone marrow failure syndromes (IBMFS):
Familial platelet disorder with propensy to myeloid malignancies (RUNX1); Thrombocytopenia 2 (ANKRD26); Familial AML with CEBPA; Familial AML with DDX41; Thrombocythopenia 5 (ETV6); Familial MDS/AML with mutated GATA2; Telomere syndromes (DC); Familial aplastic anemia with SRP72 mutation; Li-Fraumeni syndrome (Therapy related disorders)
Inherited predisposition to ataxia, pancytopenia and myeloid malignancies due to SAMD9 or SAMD9L germline mutation (Ataxia pancytopenia syndrome)

NGS targeted sequencing after hybridization capture, Home brew assay.

Confirmation of germinal status request skin biopsy or fibroblasts'DNA.

INFORMED CONSENT REQUESTED BEFORE TESTING:
http://www.chu.ulg.ac.be/jcms/c_10919499/formulaire-de-consentement-ngs
Accredited:
AZ St-Jan Brugge - Laboratoriumgeneeskunde hematology - myeloid gene panels Helena Devos/Friedel Nollet
Qiagen GeneRead custom panel. Genes : ASXL1; CALR; CSF3R; DNMT3A; FLT3; IDH1; IDH2; JAK2; KIT; MPL; NPM1; RUNX1; SETBP1; SF3B1; SRSF2; TET2; TP53; U2AF1; WT1.
Version date: 12/09/2017
Accredited:
Jessa Hospital hematology - myeloid gene panels Dr. Brigitte Maes, Guy Froyen
AmpliSeq Myeloid panel (Illumina) (DNA + RNA)
Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
2x/week
on MiSeq
Accredited 275-MED
Version date: 03/08/2021
Accredited:
AZ Delta hematology - myeloid gene panels Geert Martens, Elke Boone
Sample type: blood / bone marrow (300µl - 1 ml)
Frequency: 1x/month
Test type: TruSight Myeloid (Illumina), NGS
Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
Version date: 05/12/2017
Accredited:
UZ Brussel - Molecular Pathology hematology - myeloid gene panels Freya Vaeyens
NGS targeted sequencing after hybridization capture, home brew STHT assay (solid and hematological tumors)
Genes list available at http://www.brightcore.be/stht
Sample Type: blood/ bone marrow
Frequency: 1x/week
Accreditation: BELAC 141-MED
Version date: 10/10/2019
Accredited:
LHUB-ULB hematology - myeloid gene panels Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week; max TAT: 4 weeks
TEST TYPE: In-house developed gene panel using the Qiaseq Targeted DNA custom Panels platform (Qiagen) to screen clinically relevant genes in myeloid disorders:
ASXL1, CALR, CSF3R, DNMT3A, ETNK1, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PLCG2, RHOA, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53,U2AF1, WT1
BELAC accreditation number 650-MED

The same gene panel is also used in certain T-cell lymphoid malignancies such as AITL
Version date: 04/10/2021
Accredited:
LHUB-ULB hematology - myeloid gene panels Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week; max TAT: 4 weeks
TEST TYPE:In-house developed gene panel using the Qiaseq Targeted DNA custom Panels platform (Qiagen) to screen for driver variants in presumed polycythemia vera and essential thrombocytosis:
CALR, CSF3R, ETNK1, IDH1, IDH2, JAK2, KRAS, MPL, NRAS, SETBP1, SF3B1, SRSF2, TP53, U2AF1
1x/week
BELAC accreditation number 650-MED
Version date: 04/10/2021
Accredited: